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Chapter 1 
 
GENERAL INTRODUCTION 
 
1.1 Aging and Brain 
 
Aging is a natural process that is defined as a progressive 
deterioration of biological functions after the organism has attained its 
maximal reproductive competence. The most prominent characteristics 
of aging are a progressive decrease in physiological capacity, a reduced 
ability to respond adaptively to environmental stimuli, an increased 
susceptibility to diseases, and an increased mortality. Many theories 
have been advanced to explain aging, but the biological mechanism(s) 
that underlies aging is(are) still unknown.  
Aging produces several changes in human brain. The human brain 
shrinks with aging. It is known that decreasing in weight and volume in 
aging brain is due to a loss of neurons and myelinated axons (Peters, 
2002). Changes in brain white matter are prominent features of the 
aging brain. During aging an increase in microglial activation also 
occurs in several brain regions, including the hippocampus (Finch and 
Cohen, 1997). Possible mechanisms may include microglial reaction to 
advanced glycation end products (AGEPs) (Morgan et al., 1999), which 
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activate nuclear transcription factor kappaB (NFkB) and induce the 
transcription of pro-inflammatory cytokines during aging (May and 
Ghosh, 1998). Thus, age dependent alterations in gene expression cause 
a disruption of metabolic homeostasis (Mattson, 2002; Mocchegiani et 
al., 2006). 
Normal brain aging is associated with chronic low-grade 
inflammation. A growing amount of literature is related to the 
development of dementia and in particularly Alzheimer‘s Disease 
(AD), which is a heterogeneous and progressive neurodegenerative 
disease that in Western societies accounts for the majority of clinical 
dementia. 
Many inflammatory mediators have been detected in regions of the 
brain of patients with AD and astrocyte and microglial cells activation 
has a fundamental role in the inflammatory pathogenesis, as stated by 
the amyloid cascade/neuroinflammation hypothesis (Eikelenboom P, et 
al 2006). 
Astrocytes are responsible for the production of the neurotoxic 
substances, such as reactive oxygen and nitrogen species, pro-
inflammatory cytokines, complement proteins and other inflammatory 
mediators that bring important neurodegenerative changes (Vasto S, et 
al 2006). 
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The microglia activation can be due to local or systemic 
inflammation. In fact, a strong local inflammatory stimulus such as a 
previous head trauma is a risk factor for AD and several 
epidemiological studies clearly show that blood elevations of acute 
phase proteins, markers of systemic inflammatory stimuli, may be risk 
important factors for cognitive decline and dementia (Balistreri CR, et 
al 2008; Vasto S, et al 2007). 
It has been seen that several genetic and environmental factors are 
involved in AD onset as recently reviewed (Listì F, et al 2006), thus 
confirming that the inflammatory status cannot be per se the only ―hit‖ 
or condition able to force the development of the pathogenesis 
(Franceschi F , et al 2000).  
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1.2 Alzheimer’s Disease 
Clinically and pathologically Alzheimer‘s disease (AD) represents a 
sequential progressive neurodegenerative disorder. AD is etiologically 
heterogeneous and accounts for a majority of dementia in Western 
societies. It was identified for the first time by Alois Alzheimer, a 
Bavarian psychiatrist, who defined the pathological syndrome in a 
woman named Auguste D., showing several cardinal features of the 
disorder that are currently observed in most patients (Maurer et al., 
2007). Symptoms like progressive memory impairment, disordered 
cognitive function and altered behaviour including paranoia, delusions, 
loss of social appropriateness, and a progressive decline in language 
function are common in many patients affected by AD. The first phase 
of this gradual, relentless process, is characterized by well conserved 
patient's awareness, and intact mechanical and sensory functions 
(McKhann et al., 1984). However, as individuals keep on losing ground 
cognitively, occupations such as walking and movement 
synchronization often resemble extra-pyramidal motor disorders similar 
to Parkinsonism (Allan et al., 2005).  
The most important risk factor for AD is age. AD prevalence is 
approximately 1% between 65 and 69 years and it is higher than 50% in 
individuals above 95 years. Although the mean age of AD onset is 
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around 80 years, early-onset disease, defined arbitrarily as the illness 
occurring before the age of 60, can happen - though it is rare. Thus, 
early-onset cases make up about 6–7% of all AD evaluation (Aronson 
et al., 1991; Campion et al., 1999).  
Besides aging, which is the most obvious risk factor for the disease, 
epidemiological studies have suggested several tentative associations. 
Some can be linked to a decreased reserve capacity of the brain, 
including reduced brain size, low educational and occupational 
attainment, low mental ability in early life, and reduced mental and 
physical activity during late life.  
The brain reserve capacity is determined by the number of neurons 
and their synaptic and dendritic arborisation together with lifestyle-
related cognitive strategies. A low reserve capacity has been linked 
with early presentation of some pathological changes of the disease 
(Mayeux R. 2003; Mortimer JA et al 2003). 
Whether a brain trauma initiates the pathogenic cascade leading to 
plaque and tangle formation or whether it simply reduces the brain 
reserve capacity is unclear. Other risk factors are associated with 
vascular disease, including hypercholesterolemia, hypertension, 
atherosclerosis, coronary heart disease, smoking, obesity, and diabetes. 
Whether these are true causal risk factors for Alzheimer‘s disease, 
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driving the pathogenic processes resulting in plaque and tangle 
formation, or whether they induce cerebrovascular pathology, which 
adds to clinically silent disease pathology thus exceeding the threshold 
for dementia, needs to be established. 
Although environmental factors might increase the risk of sporadic 
Alzheimer‘s disease, this form of the disease has been shown to have a 
significant genetic background. A large population based twin study 
showed that the extent of heritability for the sporadic disease is almost 
80% (Gatz M, et al  2006). 
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1.3 Pathophysiology of AD 
Neuro-pathological hallmarks are senile plaques and neurofibrillary 
tangles in the medial temporal lobe structures and cortical areas of the 
brain (Fig. 1), together with a degeneration of the neurons and synapses 
(Nussbaum and Ellis 2003; Findeis M.A 2007).  
 
 
Fig. 1. Plaques and tangles in the cerebral cortex in Alzheimer’s disease 
Plaques are extracellular deposits of Aβ surrounded by dystrophic neurites, 
reactive astrocytes, and microglia, whereas tangles are intracellular aggregates 
composed of a hyperphosphorylated form of the microtubule-associated protein 
tau. 
 
 
Extracellular senile plaques result from the accumulation of several 
proteins and an inflammatory reaction around deposits of amyloid. It is 
a fibrillar protein (Aβ), produced by the cleavage of a much larger 
protein, the β-amyloid precursor protein (APP), by a series of proteases 
(Akiyama et al., 2000; Findeis, 2007). The senile plaques are believed 
to evolve over a long period of time and the fibrillary nature is due to 
42 amino acid long Aβ peptide accumulation. Besides, Aβ plaques 
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contain dystrophic neurites, activated microglia and reactive astrocytes 
(Rogers et al., 1988; Dickson et al., 1988; Akiyama et al., 2000). 
Aggregated amyloid fibrils and inflammatory mediators secreted by 
microglial and astrocytic cells equally contribute to neuronal dystrophy 
(Nussbaum and Ellis, 2003; Findeis, 2007).  
Neurofibrillary tangles are intracellular deposition of 
hyperphosphorylated degenerate filaments, which result from 
aggregations of the microtubular protein tau (Selkoe, 2001).  
The abnormal hyperphosphorylation of tau makes it resistant to 
proteolysis and this might lead to several-fold increase in the levels of 
tau in AD. The hyperphosphorylated tau causes sequestration of normal 
tau and other microtubule-associated proteins, leading to inhibition and 
disruption of microtubules and impaired axonal transport (Iqbal K et al  
2005).  
Tau also becomes prone to aggregation leading to formation of 
intracellular neurofibrillary tangles, compromising neuronal and 
synaptic function. 
Neurofibrillary tangles are not an exclusive marker of AD: they also 
feature in other neurodegenerative diseases named tauopathies. Among 
these pathologies, Fronto-Temporal Dementia with Parkinsonism 
(FTDP-17), an hereditary disease associated to numerous tau 
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mutations, is characterized at cellular level by deposition of paired 
helical filaments (PHF, Kidd, 1963) of hyperphosphorylated tau 
(Hutton et al., 1998). 
Under physiological conditions, APP is processed by the non-
amyloidogenic pathway, where cleavage by α-secretase releases a 
soluble fragment. In AD, this process is significantly altered, where 
increased amount of APP is cleaved by other endo-proteases such as β- 
and γ-secretase, generating highly amyloidogenic protein molecules of 
40-42 amino acid residues. 
APP is the Aβ peptide precursor and it is a transmembrane 
glycoprotein widely expressed (it is also present on platelets), produced 
by the endoplasmatic reticulum and mainly involved in the neuronal 
and dendritic growth, and synapses formation (Priller et al., 2006).  
The catabolitic feature of APP is influenced by different enzymes as 
α-β-γ secretases (PS1 and PS2 are co-factors in the processing of APP 
by secretases); as regards the different enzymes, different amounts of 
Aβ can be produced. APP is processed by two competing pathways: the 
amyloidogenic and the non-amyloidogenic . 
The amyloidogenic pathway is due to the consecutive action of two 
proteases, β- and γ-secretases, catalysing the release of the N- and C-
terminal of the protein, respectively producing Aβ40 and Aβ42 
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isoforms. In the non-amyloidogenic pathway, α-secretase protects the 
protein from amyloidogenic changes by cleaving within the Aβ 
sequence (Fig. 2). 
The peptide Aβ40, which constitutes most of the 90% secreted Aβ 
protein, is more soluble and less amyloidogenic compared to the Aβ42 
isoform. The great part of amyloid tissue is constituted by Aβ42 
isoform which is highly amyloidogenic (Selkoe, 2001; Findeis, 2007).  
This peptide is highly neurotoxic especially due to the self 
aggregation and its capacity to form insoluble plaques either in vitro or 
in vivo (Nussbaum and Ellis, 2003; Findeis, 2007; Newman et al., 
2007). 
The amyloid cascade hypothesis is the central hypothesis for the 
cause of AD, which states that the initiating event in AD is an 
imbalance between the production and clearance of Aβ in the brain. 
Support for this hypothesis includes the finding that the mutations 
implicated in the familial disease are present in the genes for both the 
substrate (APP) and the key enzyme (presenilin) for Aβ generation. 
Most APP mutations also cluster around the secretase sites, and both 
the APP and presenilin mutations increase Aβ42 production (Blennow 
K et al 2006). 
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Furthermore, the knowledge that people with Down‘s syndrome, 
who possess an extra APP gene, develop Aβ plaques early in life, and 
the recent finding of a duplication of the APP locus in families with 
familial Alzheimer‘s disease, support the notion that life-long APP 
over-expression triggers Aβ deposition (Rovelet-Lecrux A et al 2006). 
Another neuropathological hallmark of AD is the appearance of 
neurofibrillary tangles that consist of a hyperphosphorylated form of 
the microtubule-stabilizing protein tau, often conjugated with ubiquitin. 
The abnormal hyperphosphorylation of tau makes it resistant to 
proteolysis and this might lead to several-fold increase in the levels of 
tau in AD. 
The hyperphosphorylated tau causes sequestration of normal tau and 
other microtubule-associated proteins, leading to inhibition and 
disruption of microtubules and impaired axonal transport. Tau also 
becomes prone to aggregation leading to formation of intracellular 
neurofibrillary tangles, compromising neuronal and synaptic function. 
Tau pathology starts early in the disease process in neurons in the 
transentorhinal region, spreads to the hippocampus and amygdala, and 
later to the neocortical association areas. Whether tau 
hyperphosphorylation and tangle formation are a cause or a 
consequence of Alzheimer‘s disease is unknown. 
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Recently, a number of researchers showed that the levels of 
transcripts for a number of pro-inflammatory markers were elevated in 
AD, specifically in response to tau (Yoshiyama et al., 2007; Klein et 
al., 2009; Wang et al., 2010). Although a relationship between 
neurofibrillary degeneration and β-amyloidosis is debatable, it is certain 
that hyperphosphorylation of tau is related to neuroinflammation and 
could be responsible for the progression of AD. 
 
 
 
Fig. 2. Schematic representation of APP processing and Aβ accumulation. Mature 
APP is metabolized by 2 competing pathways, the α-secretase pathway that generates 
sAPPα and C83, and the β-secretase pathway that generates sAPP β and C99. C99 is a 
substrate for γ-secretase, generating Aβ. Aβ aggregates into small multimers (dimers, 
trimers, etc.) known as oligomers. 
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1.4 Genetics 
Although the complete etiopathogenesis of AD still remains unclear, 
genetic studies have provided valuable insights into this complex and 
heterogeneous disorder. Twin and family studies have shown that 
certain genes contribute to the development of AD, especially with 
respect to the age at which the disease manifests, and more recently, the 
development of non-cognitive symptomatology. Early onset familial 
AD is a very rare autosomal dominant disorder caused by highly 
penetrant mutations in APP and presenilin genes, both linked to Aβ 
metabolism. Around twelve different mutations have been identified in 
APP gene at the level of α-, β-, or γ-secretase cleavage sites, which can 
lead to alteration in the normal proteolysis of amyloid precursor 
protein. Similarly, more than fifty missense mutations of the presenilin-
1 gene (PS1) are associated with familial AD; several mutations of 
presinilin-2 gene (PS2) are associated with rare cases of early onset 
familial AD (Crentsil V. 2004; Cacabelos R 2002). 
These mutations of APP, PS1 and PS2 may share a common 
pathogenetic mechanism leading to accumulation of β-amyloid protein 
as a result of abnormal amyloid precursor protein metabolism. 
In contrast, sporadic AD is a very common disorder. Many studies 
have reported association of the APOE-4 allele with late-onset AD, and 
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APOE-2 has shown a protective effect. Moreover, APOE-4 may 
influence AD pathology by interacting with APP metabolism and Aβ 
protein accumulation, enhancing hyperphosphorylation of tau protein 
and neurofibrillary tangle formation, reducing choline acetyltransferase 
activity, increasing oxidative processes, modifying inflammation-
related neuroimmunotrophic activity and glial activation, altering lipid 
metabolism, lipid transport and membrane biosynthesis in sprouting 
and synaptic remodelling, and inducing neuronal apoptosis (Vasto S et 
al 2008; Scapagnini G et al 2010). 
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1.5 Inflammation in AD 
Inflammation is a complex cellular and molecular response to insults 
(stress, injury or infection), an attempt to defend against these insults. 
Inflammation is also a process that has been closely related to the onset 
of various neurodegenerative diseases, including AD. 
This inflammatory response in neurons (neuroinflammation) 
includes activation of microglia, astrocytes, macrophages and 
lymphocytes, resulting in the release of inflammatory mediators such as 
cytokines, chemokines, neurotransmitters and ROS (Tansey et al, 
2007).  
The release of mediators leads to recruitment of monocytes and 
lymphocytes through the blood brain barrier (BBB) (Lossinsky and 
Shivers, 2004; Taupin, 2008) as well as activation of additional 
microglia, promoting their proliferation, and resulting in further release 
of more inflammatory factors (Das and Basu, 2008). The emerging 
evidence suggests that inflammatory responses contribute to the 
progress of AD, accelerating the course of the disease. 
The major players involved in the inflammatory process in AD are 
thought to be the microglia and the astrocytes and possibly to a less 
extent the neurons, all of which are cellular components of the brain 
who have many critical roles in the homeostasis and function of the 
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brain (Akiyama et al., 2000a,b). The microglia are cells that support 
and protect the neurons and their functions in the CNS and act as 
immunocompetent defense cells that orchestrate the endogenous 
immune response of the CNS.  
The microglia are composed mostly of mesodermally derived 
macrophages (Streit&Kincaid-Colton, 1995) and they are able to 
express major histocompatibility complex type II (MHC II), pro-
inflammatory cytokines, chemokines, reactive oxygen species, and 
complement proteins (Tuppo and Arias 2005 ). Microglia also express 
scavenger receptors that mediate adhesion of the microglia to Aβ fibril-
coated surfaces, leading to ROS secretion and cell immobilization (El 
Khoury et al., 1996). Secretion of ROS can result in further neuronal 
damage.  
Microglia activated by Aβ show an increase in cell surface 
expression of MHC II protein along with increased secretion of 
proinflammatory cytokines IL- 1β, IL-6, and TNF-α, the chemokines 
IL-8, macrophage inflammatory protein-1α (MIP-1α), and monocyte 
chemoattractant protein-1. Although microglia have neuroprotective 
functions, neurotoxic mechanisms involving continuous activation of 
microglia and toxic factors released by microglia, may lead to 
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neuroinflammation. Subsequently, the continuous activation of 
microglia may act as trigger for the progression of AD pathology. 
The role of astrocytes in the inflammatory process associated with 
AD is more difficult to ascertain. Senile plaques in the AD are known 
to be associated with reactive astrocytes (Dickson, 1997) and astrocytes 
cluster at sites of Aβ deposits. Similar to microglia, they also secrete 
various proinflammatory molecules such as ILs, prostaglandins, 
leukotrienes, thromboxanes, coagulation factors, complement factors, 
proteases, and protease inhibitors.  
The aggregation of astrocytes around Aβ deposits in AD suggests 
that these lesions produce chemotactic molecules that induce astrocyte 
recruitment. 
Astrocytes activated by Aβ produce chemokines, cytokines, and 
ROS that may result in neuronal damage. Chemokines released by 
astrocytes attract microglia, which further express proinflammatory 
products, thus increasing neuronal damage in the pathogenesis of AD 
(Fig. 3). 
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Fig. 3. Schematic representation of inflammation-mediated neuronal loss in 
Alzheimer‘s disease and possible preventive effects of NSAIDs and PPAR-γ agonists. 
 
In addition to the observation that inflammatory mediators are 
present in AD lesions, there is also epidemiological and genetic 
evidence showing that inflammation contributes to AD pathology. 
Prospective case–control studies show that higher serum levels of some 
acute-phase proteins and cytokines, as C-reactive protein, alpha1-
antichymotrypsin, interleukin (IL)-6 are a risk factor for the 
development of cognitive decline and AD (Dik et al., 2005; Perry, 
2004; Schmidt et al., 2002; Licastro and Chiappelli, 2003; Yaffe et al., 
2003). 
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The polymorphisms of cytokines and other inflammatory genes 
seem to be a genetic risk factor for AD. Moreover, the inflammatory 
hypothesis is further supported by the epidemiologic finding of reduced 
incidence of AD in patients who use anti-inflammatory drugs compared 
to controls (Hoozemans and O‘Banion, 2005; int‘Veld et al., 2001; 
McGeer and McGeer, 1998). 
Other studies suggested that non-steroidal anti-inflammatory drugs, 
could be the key of the protective effect, actually anti-inflammatory 
drugs do not only inhibit ciclo-oxygenase, but also activate the receptor 
PPAR which is a transcription factor that works shutting down the 
expression of pro-inflammatory genes in mononucleate phagocyte 
(Bernardo A et al 2005). 
Further studies on the association between inflammation and AD are 
revealed in the association between dementia and the inflammatory 
marker high-sensitivity C-reactive protein (CRP) which has been 
studied in a cohort of Japanese American in the Honolulu-Asia Aging 
Study. The C-reactive protein concentrations were measured and 
associated with dementia which was assessed in a clinical examination 
that included neuroimaging and neuropsychological testing. The results 
showed that, compared with men in the lowest quartile (<0.34mg/L) of 
high-sensitivity C-reactive protein, men in the upper three quartiles had 
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a 3-fold significantly increased risk for all dementias combined, 
Alzheimer's disease, and vascular dementia. These data support the 
view that inflammatory markers may reflect not only peripheral 
disease, but also cerebral disease mechanisms related to dementia, and 
that these processes are measurable long before clinical symptoms 
appear (Schmidt R et al 2002). 
The role of an individual genetic background and predisposition for 
the extent of an inflammatory response is determined by the variability 
of genes encoding endogenous mediators that constitute the pathways 
of inflammation. Several studies report a significant different 
distribution, in patients and controls, of pro-inflammatory genes, the 
alles of which are underrepresented in control subjects and 
overrepresented in patients affected by AD (Licastro and Chiappelli, 
2003; Licastro et al., 2005, 2006; Lio et al., 2006a; McGeer and 
McGeer, 2001a). 
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1.6 Immuno-inflammatory Genes 
As reported above, inflammatory molecules might play a central role 
in AD lesion development and a number of family and case control 
studies have been directed to investigate inflammatory molecule 
variants as susceptibility candidate genes for the disease. 
Actually, the genes involved in the inflammation process are 
numerous and the role of an individual genetic background might show 
a predisposition to inflammation and its healthy or chronic resolution. 
 Primary responses are mediated by pathogen recognition receptors 
such as Toll-like receptor (TLR), pro-inflammatory cytokines such as 
TNF-α, IL-1 and IL-6, anti-inflammatory cytokines such as IL-10 and 
eicosanoids (Imahara and O'Keefe 2004; Vasto et al., 2007c). 
As such, we reviewed several data clearly showing that 
inflammatory genetic variation may contribute to AD susceptibility, 
strengthening the role of inflammation in AD. In fact, proinflammatory 
genotypes were significantly overrepresented in AD patients, whereas 
anti-inflammatory genotypes were significantly underrepresented 
(Candore et al., 2006; Candore et al., 2007; Vasto et al., 2007c). 
IL-1 overexpression seems to occur early in plaque evolution. For 
instance, it is already evident in diffuse, non-neuritic A deposits, and 
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can be observed in autopsied histochemical brain samples from fetuses 
and young children with Down‘s syndrome ( Griffin WS et al 1994).  
 The early overexpression of IL-1 in AD suggests that it could play a 
key role in plaque evolution, in particular, IL-1 promotes the synthesis 
(Mackenzie IR. 2000) and processing of APP and may therefore 
promote further amyloid production and deposition in plaques 
(Buxbaum JD, 1998). 
Also IL-6 can be measured in vivo and it reveals that elevated levels 
of IL-6 cause significant CNS damage and behavioural deficits. 
Transgenic mice that chronically overexpress IL-6 exhibit dose- and 
age-related deficits in avoidance learning that closely correlate with 
specific neuropathological changes (Heyser CJ et al 1997). 
Moreover, IL-6 has been shown to induce cellular neuropathological 
changes indicative of a chronic inflammatory response in another 
transgenic mouse model that develops motor impairment and seizures. 
Hence, pro-inflammatory cytokines seem to be involved in APP 
metabolism and in the A peptide production. 
Besides, increasing evidences suggest the involvement of innate 
immunity receptors in the activation of microglial cells. 
 The CD14 antigen/Toll like receptor-4 (CD14/TLR4) receptor 
complex seems to be overexpressed on microglial cells inducing 
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activation through the binding of Aβ peptides. This receptor complex is 
known to be involved in cellular activation by micro-organisms 
components, as lipopolysaccharide (LPS) or other highly hydrophobic 
and aggregate structures, or endogenous molecules produced by cell 
and DNA damage. So, in the AD brain all these molecules may 
contribute to development and progression of neurodegeneration 
through the TLR4/NF-kB pathway (Walter S et al 2005; Fassbender K 
et al 2004; Fassbender K et al 2004; Lehnardt S et al 2004).  
These studies will permit the detection of a risk profile which will 
potentially allow both the early identification of individuals susceptible 
to disease and the possible design or utilize of drug at the right dose for 
a desired effect, i.e., a pharmacogenomic approach for this disease. 
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1.7 Oxidative Stress and Therapeutic Perspectives 
Oxidative stress has been implicated in a variety of pathophysiological 
conditions, including neurodegenerative disorders, and oxidative 
stress–mediated neuroinflammation which has been demonstrated to 
actively participate to AD ethiopathology. 
In particular, cortical and hippocampal oxidative stress is a very 
early event in the pathogenesis of sporadic AD and correlates with the 
development of specific cognitive deficits in this condition. 
Inflammation is strictly related to ROS production, which act as signals 
to activate inflammatory genes. Actually, besides the pathological 
hallmarks of the disease, AD brains exhibit evidence of reactive oxygen 
species (ROS)–mediated injury, and free radical oxidative damage to 
key intracellular targets such as DNA or proteins has been shown to be 
a major cause of the neuronal cell death related to AD (Butterfield DA 
et al 1997).  
Oxidative stress is the result of an unbalance between oxidant 
production and antioxidant defenses. The brain, compared to other 
organs, is more susceptible to oxidative stress for the following 
reasons: (1) High content of peroxidizable unsaturated fatty acids; (2) 
high oxygen consumption per unit weight; (3) high content of lipid 
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peroxidation key ingredients (iron and ascorbate); and (4) the scarcity 
of antioxidant defenses systems.  
Within the cell, ROS are physiologically present at minimal 
concentration as byproducts of aerobic metabolism as well as second 
messengers in many signal transduction pathways and, in normal 
conditions, there is a steady-state balance between pro-oxidants and 
antioxidants 
In AD, an overproduction of free radicals seems to be mostly related 
to mitochondrial dysfunctions, to the Aβ peptides themselves, and to 
the presence of unbound trace metal ions. 
 
 
 
 
Fig. 4 Scheme of the generation and role of free radicals in AD. In cells, free radicals 
can be generated by two major sources: mitochondria and NADPH oxidase. Several 
key players,such as metals and Aβ, can exacerbate their production. Once 
accumulated inside the cell, free radicals can cause lipid, protein, DNA, and RNA 
damage that can exacerbate AD. 
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Today, it is evident that the three sources are not independent from 
each other, and recent hypotheses predict that, in the early stages of the 
disease, Aβ peptide enters the mitochondria where it induces ROS 
generation and subsequent oxidative stress (de la Monte SM, Wands JR 
2006). 
Aβ soluble oligomers, which have been shown to be cytotoxic via 
the formation of ROS, represent another source of oxidative stress, as 
well as the activation of microglial oxidase and the inflammatory 
response (Calabrese V et al 2006; Vasto S, 2007). These conditions 
well explain why the biomarkers of lipid peroxidation, such as free 4- 
hydroxynonenal (HNE), are abundantly present in several areas of the 
AD brain. Furthermore the presence of carbonylated-, HNE- and 
nitrated-proteins demonstrates the occurrence of protein modification 
by oxidation.  
Signs of oxidative damage in AD patients have also been found in 
the cerebrospinal fluid, in urine, and in serum and, although the results 
of some studies are contradictory, it seems that the levels of oxidative 
damage parallels the progression of the disease (Butterfield DA, 
Sultana R.2007; Scapagnini G, et al 2010). 
All together these findings suggest that increased oxidative damage 
is not the terminal sequelae of the disease but instead it plays an initial 
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role. They also suggest that damage does not mark further destruction 
by reactive species and is instead marked by a broad array of increased 
cellular defenses (Perry et al., 2002). 
Aging, the major risk factor for AD, leads to loss of free radical 
scavenging ability by endogenous mechanisms and it is widely known 
that free radical‑induced oxidative stress increases in brain aging. 
Oxidative damage to key intracellular targets such as DNA or proteins 
by free radicals has been shown to be a major cause of the neuronal cell 
death related to AD. 
Since oxidative stress may underlie some - if not all - aspects of AD 
neurodegeneration and since to date most of the available treatments 
are merely symptomatic, a considerable research has been aimed at 
reducing the effects of oxidative stress in order to prevent AD progress, 
by using free radical scavengers. Thus, one therapeutic strategy is to 
delay the onset of AD dementia sufficiently long as to slow the 
neuronal damage associated with Aβ‑induced oxidative stress, 
particularly Aβ‑induced lipid peroxidation (Finkel T, Holbrook 
NJ.2000; Hensley K et al 1995, Sultana R et al 2006). 
Brain‑accessible antioxidants potentially may provide the means of 
implementing this therapeutic strategy of delaying the onset of AD, 
acting as neuroprotective agents. 
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By definition, neuroprotection is an effect that may result in salvage, 
recovery or regeneration of the nervous system, its cells, structure and 
function. Although there are several lines of evidence supporting the 
hypothesis that neuroprotection may be a practical and achievable 
pharmacological target, few effective compounds have been developed 
for clinical application. 
One of the more important system devoted to the antioxidant 
defense in brain is represented by the ―heat shock proteins‖ (Hsps) and 
among the Hsps family, an important role has been attributed to heme 
oxygenase-1 (HO-1 or Hsp-32). 
HO-1 catalyzes the conversion of heme to biliverdin and iron. 
Biliverdin, in turn, is reduced to bilirubin, an antioxidant. Since HO-1 
is induced in proportion to the level of heme (Keyse and Tyrrell, 1989), 
the induction of HO-1 suggests that there may be abnormal turnover of 
heme in AD. 
In the CNS, the HO system has been reported to be very active and 
its modulation seems to play a crucial role in the pathogenesis of 
neurodegenerative disorders. Deregulation of the HO system has been 
associated with the pathogenesis of Alzheimer‘s disease, multiple 
sclerosis and brain aging (Takeda A et al 2000; Schipper HM. 2000). 
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Many studies clearly demonstrate that activation of HO‑1 in neurons 
is strongly protective against oxidative damage and cell death. In fact, 
the activation of HO‑1 seems to represent an important defensive 
mechanism for neurons exposed to oxidative stress (Chen K et al 2000; 
Panahian N et al 1999). 
Thus, modulation of HO‑1 should represent a potential 
pharmaceutical strategy for the treatment of neurodegenerative 
disorders. Because oxidative stress may be responsible for some 
aspects of AD neurodegeneration, extensive research has been aimed at 
reducing the effects of oxidative stress to prevent AD progression by 
using free radical scavengers. In recent years there has been a growing 
interest, supported by a large number of experimental and 
epidemiological studies, in the beneficial effects of some commonly 
used food‑derived products in preventing various age‑related 
pathologic conditions, included brain aging (Racchi M et al 2008). 
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1.8 Goal of the Thesis 
The overall aim of this thesis was to study some hot topics 
concerning AD pathophysiology that have an important impact on 
therapeutic perspectives. The manuscripts included in this thesis have 
addressed different aspects of the most common form of senile 
dementia, hence we have focused our attention on inflammation, 
cytokines, immune response, oxidative stress, as well as on exploring 
the related therapeutic possibilities. 
In fact, taking into account the future epidemic of AD, prevention 
and treatment are important goals of ongoing research. As discussed in 
this thesis, events contributing to the onset and development of AD are 
numerous and complex. I believe that the investigation of AD 
pathophysiology, particularly disentangling inflammation, is likely to 
provide important clues about how to develop drugs that can slow or 
delay AD. 
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Chapter 7 
 
GENERAL DISCUSSION 
 
Biomarkers of Aging 
Whereas the average life span of a population is relatively stable, on 
the level of the individuals, it has a big variation. On the other hand, the 
rate of aging in humans is not uniform, due to genetic heterogeneity 
and the influence of environmental factors. Thus, the aging rate, 
measured as the decline of functional capacity and stress resistance, 
seems to be different in each individual (A.L. Goldberger, et al 2002). 
Therefore, attempts have been made to analyse this individual age, the 
so-called biological age, in comparison to chronological age. 
 Age-related changes in body function or composition that could 
serve as a measure of biological age and predict the onset of age-related 
diseases and/or residual lifetime are termed biomarkers of aging. Many 
candidate biomarkers have been suggested but in all cases their 
variability in cross-sectional studies is considerable, and therefore no 
single measurement has been proven so far to yield a useful biomarker 
of aging on its own, probably due to the multi-causal and multi-system 
nature of aging. 
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 Such biomarkers of aging should help on the one hand to 
characterise this biological age and, as age is a major risk factor in 
many degenerative diseases, could be subsequently used on the other 
hand to identify individuals at high risk of developing age-associated 
diseases or disabilities. However, these biomarkers might be more than 
disease risk factors, and represent individual indicators of functional 
status.  
We discuss functional parameters, including anthropometric data, 
functional challenge tests, physiological tests, oxidative stress 
assessment, genomic and proteomic tests. Such a set of functional 
biomarkers of aging would help to identify tests that had the greatest 
predictive value when matched against functional outcome and 
morbidity patterns. Those with the highest predictive value would be 
defined as functional biomarkers of aging.   
These biomarkers could be used to develop personalized medicine or 
other interventions which effectively reduce morbidity and improve 
organ-specific function by delaying the necessity for costly 
hospitalization or social support of the aging populations (D.F. Terry, et 
al 2006; T.E. Johnson 2006; E. Jirillo, et al 2008). 
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Inflammation, Cytokines, Immune Response, 
Apolipoprotein E, Cholesterol, and Oxidative Stress in 
Alzheimer’s Disease: Therapeutic Implications 
A better understanding of the interplay among inflammatory 
mediators, oxidative stress, and acquired immunity is necessary to 
understand AD development.  
AD prevention is an important goal of ongoing research. Two 
objectives must be accomplished to make prevention feasible: 
 i) individuals at high risk of AD need to be identified before the 
earliest symptoms become evident, by which time extensive 
neurodegeneration has already occurred and intervention to prevent the 
disease is likely to be less successful and ii) safe and effective 
interventions need to be developed that either reduce or slow the 
accumulation of AD neuropathology or lead to a decrease in clinical 
expression of this pathology (Vasto S, et al  2007). 
APOE, cholesterol, and AD has been the subject of intense scrutiny 
by numerous groups. Since cholesterol levels at midlife are a 
considerable risk factor for dementia/AD in most of long term follow-
up studies. 
The best studied role of cholesterol in AD is in amyloid precursor 
protein (APP) processing and Aβ generation. Increased cholesterol 
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leads to increased cleavage of APP and increased Aβ production, 
whereas reduction of cellular cholesterol decreases the γ-secretase 
activity, which is responsible for Aβ generation (Vasto S, et al 2008; 
Kivipelto M, et al 2006; de Chaves EP, et al 2008). 
Epidemiological studies have suggested a possible protective effect 
for the cholesterol-lowering statin drugs that inhibit 3-hydroxy-3-
methyl-glutaryl-coenzyme A reductase the enzyme that catalyzes the 
rate-limiting step in cholesterol, in AD patients numerous studies have 
examined the role of statins in the prevention of dementia and treatment 
of established AD. 
Besides cognitive impairment can be influenced by a number of 
other factors. The potential effect of nutrition has become a topic of 
increasing scientific and public interest. 
In particular, there are arguments that nutrients (food and/or 
supplements), such as vitamins, trace minerals, and lipids, can affect 
the risk of cognitive decline and dementia, especially in frail elderly 
people at risk of deficiencies. 
Aging is associated with cognitive dementia and AD; concomitantly, 
aging is also associated with malnutrition and reduced intake of micro- 
and macronutrients. The role of diet in cognitive decline has not been 
looked into broadly, but because several dietary factors affect the risk 
106 
 
of cardiovascular disease and some studies have suggested a link 
between cognitive decline and cardiovascular disease, diabetes 
mellitus, and hypertension, it might be assumed that dietary intake 
might also influence the risk of dementia (Breteler MM et al 1994;  
Naor M et al 1997;  Guo Z et al 1997). 
Diets enriched with anti-oxidant and anti-inflammatory agents 
(curcumin, green tea, and ferulic acid) may lower the risk of developing 
age-related neurodegenerative diseases such as AD and PD. Many 
studies indicate that dietary supplementation with fruit or colored 
vegetable extracts can decrease the age-enhanced vulnerability to 
oxidative stress and inflammation. Additional studies indicate that 
polyphenolic compounds found in red wine and fruits such as 
blueberries may exert their beneficial effects through signal 
transduction and neuronal communication, delaying dementia 
(Ruitenberg et al., 2002; Lau et al., 2007; Joseph et al., 2007).  
 Other food-based antioxidants (such as vitamins C and E, b 
carotene, curcumin, and green tea) may modulate primary as well as 
secondary processes of aging by neutralizing free radicals. An 
imbalance between free radical production and anti-oxidant defense 
leads to an oxidative stress state, which may be involved in aging 
processes and even in some pathologies. Therefore, diet enrichment 
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with antioxidants may protect brain tissue and result in successful aging 
(Cabrera et al., 2006).  
 
Immune-Inflammatory Responses and Oxidative Stress 
in Alzheimer’s Disease: Therapeutic Implications 
 
Increasing evidence has supported the possibility that 
neuroinflammation significantly contributes to the pathogenesis of AD. 
Knowledge about the roles of both microglia and astrocytes, and the 
action of proinflammatory mediators in neurodegenerative diseases, 
supports the hypothesis that neuroinflammation causes progression of 
AD pathology. 
In particular, the production and secretion of proinflammatory 
mediators may interact with various mechanisms, with the initiation 
and progression of neurodegeneration. 
Variations in immune-inflammatory genes such as cytokine, cyclo-
oxygenase, lipo oxygenease, toll-like receptors have also been 
considered to be important in the risk for AD (Vasto S et al 2008). 
In particular, cytokine gene polymorphisms have been claimed to 
play a key role in pathophysiology of AD, as demonstrated by two 
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recent meta-analysis performed by our group on IL-1β and TNF-α (Di 
Bona DI et al  2009;  Di Bona DI et al 2008). 
Therefore, we present data on a meta-analysis focused on IL-6. IL-6 
is a pleiotropic cytokine involved in the regulation of the acute 
inflammatory response. Microglia, astrocytes, neurons, and endothelial 
cells seem capable of synthesizing IL-6.  Although IL-6 overexpression 
is generally detrimental, there are evidences that it may have also 
trophic properties under restricted conditions and levels of exposure. 
For example, it has been suggested that IL-6 plays a key role in 
regulating neuronal survival and function and it may be essential for 
neuron and astrocyte differentiation and increased IL-6 levels in the 
brain have been implicated in early stages of plaque formation. 
Polymorphisms in the genes regulating the expression of IL-6 have 
been hypothesized to enhance the risk of developing AD. In particular, 
the most studied polymorphism of IL-6, the G/C polymorphism at the 
position -174 in the 5‘ flanking region of IL-6 gene, was shown to be 
associated with a decreased expression and also with a reduced plasma 
level of IL-6 (Di Bona DI et al 2008; Bradt BM et al 1998; Di Bona DI 
et al  2009). 
The studies were selected and analysed according to criteria and 
methods discussed and in particular the putative risk genotype in 
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homozygosity (GG) was compared to the other two aggregated 
genotypes data (CG+CC), condensing the results into one statistic. The 
current meta-analysis summarizes the evidence regarding the 
association between IL-6 -174 SNP and AD, representing a pooled total 
of 3811 cases and 10716 controls. The analysis of pooled data ruled out 
the role of IL-6 -174 SNP in modifying AD risk that was hypothesized 
by some investigators. However, a remarkable heterogeneity was 
observed between the results of individual studies, suggesting 
differences among the enrolled populations, and a possible population 
specific genetic effect of the -174 IL-6 SNP. Also genetic or 
environmental factors may play a contributing role and may explain 
differences between the results of individual studies. 
So, these data do not apparently support a role for this IL-6 SNP in 
pathophysiology of AD. However, it is to take into account that 
inflammatory mediators do not act alone but they act in a complex 
network reciprocally interacting (Vasto S et al 2007). 
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Association between the Polymorphisms of TLR4 and 
CD14 Genes and Alzheimer’s Disease 
Several membrane proteins expressed on microglial cells seem to be 
implicated in Aβ peptides binding. It has been demonstrated that 
CD14/TLR4 receptor complex binds highly hydrophobic Ab peptides 
aggregates suggesting that production of neurotoxic substances. This 
receptor complex is known to be involved in cellular activation by 
micro-organisms components, as lipopolysaccharide (LPS) or other 
highly hydrophobic and aggregate structures, or endogenous molecules 
produced by cell and DNA damage. 
The key role of this receptor complex leads to biologically plausible 
hypothesis that functional variations in the TLR4  and CD14 genes 
might influence the susceptibility to sporadic AD. 
Evidence discussed here indicates the involvement of genetic TLR4 
variations in the attainment of longevity and in the susceptibility to 
these age-related diseases, since TLR4- mediated inflammation from 
bacterial and viral infection or other endogenous molecules can 
influence the development of these diseases. Given the complex 
inheritance patterns of these polygenetic traits, the impact of any single 
allele on the trait under study is obviously modest. 
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The Asp299Gly SNP might result in an increased chance of 
longevity in a modern environment with reduced pathogen load and 
improved control of severe infections by antibiotics. Finally, our data 
prompt consideration of the role that antagonistic pleiotropy plays in 
diseases and longevity (Capri M et al 2008; Licastro F et al 2005). 
The search for a pro-inflammatory profile is of some importance for 
a pharmacogenomic approach, i.e. to detect and utilize a risk profile 
which allows early identification of individuals at risk dose for desired 
effects. Accordingly, carriers of high responder polymorphisms, 
affected by mild cognitive impairment might be selected for a clinical 
trial on antibiotic prophylaxis for the prevention of AD (EL,Gross H. 
2008). 
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Pathophysiology of Vascular Dementia 
Alzheimer‘s disease (AD) and vascular dementia are the most 
common forms of cognitive impairment in the elderly. The pathogenic 
mechanisms underlying these two conditions have traditionally been 
considered separate, even mutually exclusive (Erkinjuntti T, Gauthier S 
2009). 
Diagnostic criteria were drafted and widely applied, establishing AD 
as the predominant cause of senile cognitive impairment, a course of 
action aptly referred to as ―alzheimerization‖ of dementia (Libon DJ et 
al 2006).  
On the other hand, vascular dementia evolved from the concept of 
‗‗arteriosclerotic dementia‘‘, in which hardening of cerebral arteries 
leads to diffuse ischemia and neuronal loss, to ―multiinfarct dementia‖, 
caused by multiple infarcts resulting in cognitive impairment due to 
progressive brain loss (Hachinski VC et al 1974). In the early 1990s, 
the broader term ―vascular cognitive impairment‖ (VCI) was 
introduced to encompass the wide spectrum of cognitive alterations 
associated with cerebrovascular pathologies, including more subtle 
deficits that would not fulfill AD criteria (Hachinski VC, Bowler JV 
1993). 
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These observations, together with epidemiological studies indicating 
that AD and cerebrovascular diseases share the same risk factors, have 
revived the interest in the idea that vascular factors may play a role in 
the pathogenesis of AD (Petersen RC: 2000; Leblanc GG, et al 2006;  
Rockwood K,  et al 2000). 
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Chapter 8 
 
 
CONCLUSIONS 
 
Alzheimer's disease (AD) is a progressive neurodegenerative 
disorder affecting aged people; AD prevalence is approximately 1% 
between 65 and 69 years and it is higher than 50% in individuals above 
95 years. It is characterized by irreversible cognitive and physical 
deterioration. 
With increasing life expectancy across the world, dementia is a 
rapidly growing socioeconomic and medical problem. The 
confirmatory diagnosis of AD is based on the recognition and 
quantification of senile plaques and neurofibrillary tangles, which are 
the hallmarks of the disease (Vasto S, et al 2008). 
AD prevention is an important goal of ongoing research. Two 
objectives must be accomplished to make prevention feasible: i) 
individuals at high risk of AD need to be identified before the earliest 
symptoms become evident, by which time extensive neurodegeneration 
has already occurred and intervention to prevent the disease is likely to 
be less successful and ii) safe and effective interventions need to be 
developed that either reduce or slow the accumulation of AD 
115 
 
neuropathology or lead to a decrease in clinical expression of this 
pathology (Vasto S, et al 2007). 
The aim of this thesis was to illustrate the role of immune-
inflammatory response in AD and that the treatment might play a 
decisive role in preventing or significantly delaying the onset of the 
disease. So, the knowledge of the pathophysiology of the diseases is 
crucial for its therapeutic prevention. Accordingly to the data discussed 
in the present thesis, two lines of preventive therapeutics can be 
discussed, the first based on anti-inflammatory drugs, the second one 
on anti-oxidative properties. 
Concerning anti-inflammatory drugs, patients who received non-
steroidal anti-inflammatory drugs (NSAIDs) for a period of 2 years had 
lower AD incidence with relative risk of 0.2. The incidence of AD 
appears to be reduced in some post hoc studies, by about 13% for 
aspirin and 28% for other NSAIDs (in t' Veld BA, et al 2001; McGeer 
PL, et al 1996; Breitner JC. 2003; Etminan M, et al  2003). 
On the other hand, recent clinical trials showed that use of naproxen 
or celecoxib did not improve cognitive function (Martin BK, Szekely 
C, Brandt J, Piantadosi S, Breitner JC, et al 2009). 
This failure could be due to a number of factors, including the 
pharmacological characteristics of the drugs, their brain penetration 
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properties, and the dosing  schedule. It has been claimed that the 
ADAPT study does not indicate that NSAIDs, if taken during 
adulthood and for an extended period, cannot prevent or delay the onset 
of dementia (Bregman N et al 2009). 
Regarding molecules with anti-oxidant properties, a number of 
experimental and epidemiological studies have recently supported the 
beneficial effects of some commonly used natural products in 
preventing various pathologic conditions ranging from cardiovascular 
diseases to cancer. 
According to free radical theory of aging, an elevation in reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) damages 
neural membranes and induces oxidative and nitrosative stress. The 
increase in oxidative and nitrosative stress is accompanied by the 
concomitant decline in cognitive and motor performance in the elderly 
population, even in the absence of neurodegenerative diseases. 
Markedly increased rates of oxidative and nitrosative stress are the 
major factors associated with the pathogenesis of neurodegenerative 
diseases. Diet is a key environmental factor that affects the incidence of 
chronic neurodegenerative diseases.  
Dietary supplementation with polyphenols, resveratrol, ginkgo 
biloba, curcumin, ferulic acid, carotenoids, flavonoids, and n-3 fatty 
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acids exerts beneficial effects not only through the scavenging of free 
radicals, but also by modulating signal transduction, gene expression, 
and restoring optimal neuronal communication. Collective evidence 
from studies suggests that these compounds have great potential to 
combat against normal human brain aging and age-related 
neurodegenerative diseases.  
Spices and herbs often contain active phenolic substances endowed 
with potent antioxidative and chemopreventive properties and recently 
a series of papers focused on specific neuroprotective effects of some 
of those polyphenols derived from nutritional sources (Nakatani, N. 
2000; Go´ mez-Pinilla. 2008). 
Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-
3,5-dione), a coloring agent and food additive commonly used in Indian 
culinary and traditional medical preparations from time immemorial, is 
extracted from the rhizome of Curcuma longa (Ammon HPT, Wahl 
MA 1991).  
It is a polyphenolic substance that has the potential to inhibit lipid 
peroxidation and to effectively intercept and neutralize ROS 
(superoxide, peroxyl, hydroxyl radicals) and nitric oxide (NO)-based 
free radicals (nitric oxide and peroxynitrite) (Priyadarsini KI et al 1998; 
Martin-Aragon S et al 1997; Sreejayan A, Rao MN. 1997). 
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In this regard, curcumin has been demonstrated to be several times 
more potent than vitamin E. It is generally assumed that the phenol 
moiety is responsible for the antioxidant properties of any plant 
phenolic compound. Consequently, the free radical chemistry of 
curcumin has focused on its phenol ring. The possible involvement of 
the β‑diketone moiety in the antioxidant action of curcumin has been 
considered and H‑atom donation from the β‑diketone moiety to a lipid 
alkyl or a lipid peroxyl radical has been reported as the potentially 
more important mechanism underlying its antioxidant action.  
Of particular interest is the ability of curcumin to inhibit COX‑1 and 
COX‑2 enzymes and to reduce the activation of nuclear transcription 
factor NF‑kB (Masuda T et al 1999; Jovanovic SV et al 2001; Ramos-
Gomez M 2001; Singh S, Aggarwal BB.1995; Huang MT et al 1997). 
Its anti‑inflammatory properties and cancer‑preventive activities 
have been consistently reported using in vitro and in vivo models of 
tumor initiation and promotion. In addition to its ability to scavenge 
carcinogenic free radicals, curcumin also interferes with cell growth 
through inhibition of protein kinases. Although the exact mechanisms 
by which curcumin promotes these effects remains to be elucidated, the 
electrophilic properties of this yellow pigment appear to be an essential 
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component underlying its pleiotropic biological activities (Abe Y et al 
1999; Awasthi S et al 2000). 
It has been then demonstrated the ability of curcumin to induce HO-
1 in cultured hippocampal neurons. The results indicate that curcumin 
activates HO-1 and phase II enzymes expression in astrocytes and 
neurons, probably by activation of transcription factor Nrf2, and this 
activation is able to effort a significant cytoprotection in cultured 
neurons exposed to oxidative stress (Rajakrishnan V et al 1999). 
The involvement of curcumin in restoring cellular homeostasis and 
rebalancing redox equilibrium suggests that it might be a useful adjunct 
also in the treatment of neurodegenerative illnesses characterized by 
inflammation, such as AD. This idea has been reinforced by 
epidemiological studies showing that, in India where this spice is 
widely used in daily diet, there is a reduced age-adjusted prevalence of 
AD (in patients between 70 and 79 years of age is 4.4-fold less than 
that of the United States) (Chandra V et al 2001). 
Consistent with its possible use in neurodegenerative diseases, 
curcumin has been reported to decrease oxidative damage and amyloid 
deposition in a transgenic mouse model of Alzheimer's disease, and to 
reverse Aβ-induced cognitive deficits and neuropathology in rats (Lim 
GP et al 2001; Frautschy SA et al 2001). 
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Although clinical studies on cognitive impairment and specific berry 
supplementation have yet to be completed, a number of studies have 
indicated that inclusion of antioxidant-rich foods in the diet can 
improve cognitive functioning in humans. In elderly non-demented 
people, elevated dietary intake of flavonoid-rich foods was associated 
with better cognitive function (Shukitt-Hale B, et al 2009). 
Additionally, high flavonoid consumption was associated with 
attenuation of cognitive decline over a period of 10 years. Other studies 
have revealed that general dietary patterns, such as daily fruit and 
vegetable consumption and adherence to a ‗Mediterranean diet‘ 
emphasizing vegetables, fruits, beans and nuts, can decrease the risk of 
developing dementia in aging humans (Scarmeas N, et al 2009). 
Dietary supplementation with fruit or vegetable extracts decreases 
the age-enhanced vulnerability to oxidative stress and inflammation. 
Several studies have indicated that polyphenolic compounds found in 
fruits such as blueberries may exert their beneficial effects through 
signal transduction and neuronal communication. Collective evidence 
suggests that nutritional supplementation with polyphenolic compounds 
may exert therapeutic protection against age-related deficits and 
neurodegenerative diseases (Lau et al., 2007). 
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 The use of anti-aging remedies along with physical activity 
stimulate the regeneration of neurons in the old brain, and boost the 
performance of mental and physical tasks. Collective evidence suggests 
that physicians already have ‗‗anti-aging‘‘ treatments at their disposal. 
However, the influence of such treatments on life span of humans has 
not been studied.  
The increase in human life expectancy at birth in the second half of 
the last century is mostly caused by enhanced survival at old age. The 
use of neuroprotective and regenerative drugs is increasing in the 
elderly population of the Western world, and it is suggested that the use 
of medicines exerting anti-aging properties may contribute to an 
increase in human longevity. 
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Chapter 9 
 
SOMMARIO E DISCUSSIONE 
 
L‘invecchiamento è un processo multifattoriale prodotto 
dell‘interazione tra fattori genetici, ambientali e stile di vita. 
Nell‘uomo, l‘età avanzata è caratterizzata dall‘insorgenza di alcune 
patologie che, benché non siano di per sé espressione 
dell‘invecchiamento, sono però strettamente associate alla vecchiaia, in 
quanto il declino fisiologico dovuto alla progressione dell‘età conduce 
inesorabilmente l'organismo ad una condizione di maggiore 
suscettibilità e vulnerabilità nei confronti delle malattie, con 
conseguente aumento della mortalità in maniera età-dipendente. 
Nel corso del tempo molti studi sono stati indirizzati 
all‘identificazione degli eventi biologici a cui potrebbe essere 
imputabile il deterioramento progressivo che si verifica in 
concomitanza con l‘invecchiamento. 
Gran parte delle caratteristiche fenotipiche osservate nel processo di 
invecchiamento sono frutto dell‘insorgenza, con l‘età, di uno stato pro-
infiammatorio cronico di basso grado detto “Inflamm-aging”, in parte 
sotto controllo genetico: tale stato sembra essere la conseguenza della 
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continua stimolazione antigenica che continua oltre l‘età riproduttiva e 
quindi largamente non prevista dall‘evoluzione . 
L‘aumentato carico antigenico, oltre a determinare gli effetti sulla 
risposta immune specifica finisce per instaurare un‘infiammazione 
cronica che contribuisce al deterioramento dei vari organi, diventando 
un grande fattore di rischio per tutte le malattie croniche tipiche dell‘età 
avanzata, dal diabete alle malattie cardiovascolari o alle demenze.  
Infatti, gli anziani che presentano livelli ematici più alti di una 
proteina di fase acuta, la PCR, sono più soggetti ad ammalarsi delle 
patologie infiammatorie croniche e hanno un maggior rischio di 
disabilità e morte. 
Le conseguenze sistemiche determinano un pattern di modificazioni 
che va sotto il nome di ―fragilità‖ (chronic inflammatory disease or 
frailty) e gli studi epidemiologici suggeriscono che l‘infiammazione di 
modico grado osservabile nei processi d‘invecchiamento promuova un 
profilo aterogeno e sia correlata alle malattie infiammatorie croniche 
tipiche dell‘invecchiamento (Alzheimer, Diabete di tipo 2) e in ultima 
analisi a un aumentato rischio di morte. 
All‘interno di questo contesto, interazioni neuroendocrine, 
immunologiche e infiammatorie sono state chiamate in causa nella 
patogenesi della malattia di Alzheimer. L‘invecchiamento cerebrale è 
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normalmente associato ad una infiammazione cronica di basso grado, 
quindi l‘infiammazione ha un ruolo rilevante specialmente nei 
confronti dell‘AD, che rappresenta una malattia progressiva e 
neurodegenerativa che nel mondo occidentale è la causa più comune di 
demenza senile. 
Nell‘AD, i mediatori dell‘infiammazione sono prodotti dagli 
astrociti e dalle cellule microgliali e concorrono a sostenere l‘ipotesi 
neuro-infiammatoria come causa della AD. La proteina beta amiloide, 
elemento patognomico della malattia, sembra essere indotta e 
incentivata dall‘ambiente infiammatorio incrementando, a sua volta, i 
livelli della stessa infiammazione attraverso la generazione di specie 
reattive dell‘ossigeno e dell‘azoto, citochine pro-infiammatorie, 
proteine del complemento ed altri composti. 
Gli studi riportati nella presente tesi sui polimorfismi implicati nella 
regolazione della produzione delle citochine hanno dimostrato come 
possedere un genotipo caratterizzato da un‘altra produzione di 
citochine pro-infiammatorie (IL-1, IL-6, TNF-α) o da una bassa 
produzione di citochine anti-infiammatorie (IL-10) aumenti 
significativamente il rischio di ammalarsi di AD. 
Inoltre, diverse prove sperimentali ipotizzano il coinvolgimento dei 
recettori dell‘immunità innata nell'attivazione delle cellule microgliali. 
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Il complesso antigene CD14/TRL4 sembra essere maggiormente 
espresso nelle cellule microgliali causando così l'attivazione attraverso 
il legame del peptide Aβ. Il ruolo chiave di questo complesso di 
recettori porta all'ipotesi, plausibile dal punto di vista biologico, che le 
variazioni funzionali nei geni di TLR4 e CD14 possano influire sulla 
suscettibilità all'AD sporadico. 
Poiché la variabilità genetica esercita una grande influenza nello 
sviluppo dei processi infiammatori, l‘analisi di tali fattori nell‘ambito 
della complessa fisiopatologia dell‘Alzheimer, permette 
l‘identificazione di un profilo di rischio utile nell‘individuare i soggetti 
suscettibili alla malattia.  
Questo ha indirizzato il nostro interesse verso lo studio dei geni 
immuno-infiammatori, in modo tale da poter effettuare  un adeguato 
trattamento terapeutico in quei soggetti con un profilo genetico a 
rischio, permettendo una diagnosi precoce della malattia; il trattamento 
antinfiammatorio potrebbe avere un ruolo decisivo nel prevenire o nel 
ritardare notevolmente la manifestazione clinica della malattia. 
Inoltre, le specie reattive dell‘ossigeno (ROS) sono in grado di 
indurre profondi effetti sull‘espressione genica e sono implicate nella 
patogenesi dell‘AD e il danno ossidativo probabilmente è uno dei primi 
segni di disfunzione neuronale nella malattia. Lo stress ossidativo può 
126 
 
essere definito come uno squilibrio tra l‘aumentata produzione di ROS 
e le capacità di riparazione delle cellule. 
La produzione di ROS è un fenomeno che avviene normalmente nei 
tessuti come ad esempio durante la produzione di energia dai 
mitocondri, ma vi è un‘aumentata produzione a causa di fenomeni 
eccitatori, ischemici oltre che ovviamente infiammatori. D‘altronde, 
l‘invecchiamento si accompagna ad un declino dei meccanismi di 
difesa cellulare verso gli effetti dei ROS. L‘equilibrio finale può essere, 
inoltre, modificato dallo stile di vita, quale il consumo di vitamine, 
fumo di sigarette e l‘esercizio fisico. 
È noto che un regime alimentare ipocalorico, adeguatamente 
integrato con elementi nutritivi essenziali, prolunga la durata media 
della vita negli animali da laboratorio. Considerando lo stress 
ossidativo come una delle principali cause dell‘invecchiamento e delle 
patologie neurodegenerative ad esso connesse, il beneficio apportato 
dalla restrizione calorica andrebbe collegato a un abbassamento dei 
livelli di stress ossidativo e a un aumento del potenziale metabolico. I 
risultati sperimentali confermano tale ipotesi. 
Allo stesso modo anche sostanze dotate di proprietà antiossidanti o 
in grado di potenziare i sistemi endogeni di difesa dai radicali liberi 
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dovrebbero prevenire l‘insorgenza di stati di demenza, inclusa la 
malattia di Alzheimer.  
Anche nell‘uomo è stata evidenziata una possibile correlazione tra 
fattori dietetici, invecchiamento cerebrale, disfunzioni cognitive e 
rischio di demenze. 
In particolare una dieta ricca di acidi grassi e una contemporanea 
carenza di sostanze antiossidanti potrebbero aggravare e potenziare il 
danno ossidativo. 
Al contrario, una corretta integrazione alimentare con vitamina C, 
vitamina E, beta-carotene e polifenoli (tutte sostanze in grado di 
neutralizzare l‘azione dei radicali liberi) porterebbe a un miglioramento 
delle capacità cognitive.  
Queste osservazioni portano a pensare che qualsiasi trattamento 
capace di ridurre o di rallentare il processo ossidativo si inserisce, in 
questo contesto, come un possibile approccio preventivo, più che 
terapeutico, al trattamento delle patologie neurodegenerative. Se si 
pensa che una dieta ricca in antiossidanti è probabilmente una dieta 
bilanciata, ricca in vegetali e fibre, potenzialmente utile anche nella 
prevenzione di malattie cardiovascolari, al di là degli specifici 
meccanismi e delle prove scientifiche di efficacia, costituisce un 
suggerimento di stile di vita sicuramente proponibile. 
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Si potrà così impostare una terapia ed una dieta appropriata, mirate 
alla prevenzione della malattia o a ritardarne anche di molti anni la 
manifestazione e di poter quindi godere di un maggior numero di anni 
di vita sana e indipendente. 
Ancora molti studi devono essere effettuati in questo settore, non 
solo allo scopo di approfondire la comprensione dei meccanismi fini 
che regolano i processi biologici legati all'infiammazione 
nell'invecchiamento, ma anche e soprattutto per rendere disponibili 
all'uomo degli strumenti terapeutici e preventivi attendibili in un ambito 
di straordinaria importanza come quello della longevità umana. 
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